ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.38 is strong.
Zai Lab has a Altman Z-Score of 3.25, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Zai Lab's Altman Z-Score or its related term are showing as below:
During the past 9 years, Zai Lab's highest Altman Z-Score was 56.84. The lowest was 0.25. And the median was 7.30.
The historical data trend for Zai Lab's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Altman Z-Score | Get a 7-Day Free Trial | 0.30 | 55.20 | 14.05 | 7.94 | 3.72 |
Zai Lab Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Altman Z-Score | Get a 7-Day Free Trial | 6.70 | 6.13 | 3.72 | 0.96 | 0.38 |
For the Biotechnology subindustry, Zai Lab's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zai Lab's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Zai Lab's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Zai Lab's Altman Z-Score for today is calculated with this formula:
Z | = | 1.2 | * | X1 | + | 1.4 | * | X2 | + | 3.3 | * | X3 | + | 0.6 | * | X4 | + | 1.0 | * | X5 |
= | 1.2 | * | 0.6261 | + | 1.4 | * | -2.3595 | + | 3.3 | * | -0.3015 | + | 0.6 | * | 10.7786 | + | 1.0 | * | 0.3268 | |
= | 3.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Trailing Twelve Months (TTM) ended in Jun. 2024:
Total Assets was $987.4 Mil.
Total Current Assets was $869.9 Mil.
Total Current Liabilities was $251.7 Mil.
Retained Earnings was $-2,329.7 Mil.
Pre-Tax Income was -80.277 + -53.471 + -95.429 + -69.152 = $-298.3 Mil.
Interest Expense was -0.492 + -0.113 + 0 + 0 = $-0.6 Mil.
Revenue was 100.504 + 87.149 + 65.83 + 69.228 = $322.7 Mil.
Market Cap (Today) was $3,052.4 Mil.
Total Liabilities was $283.2 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
X1 | = | Working Capital | / | Total Assets |
= | (Total Current Assets - Total Current Liabilities) | / | Total Assets | |
= | (869.923 - 251.718) | / | 987.368 | |
= | 0.6261 |
X2 | = | Retained Earnings | / | Total Assets |
= | -2329.728 | / | 987.368 | |
= | -2.3595 |
X3 | = | Earnings Before Interest and Taxes | / | Total Assets |
= | (Pre-Tax Income - Interest Expense) | / | Total Assets | |
= | (-298.329 - -0.605) | / | 987.368 | |
= | -0.3015 |
X4 | = | Market Value Equity | / | Book Value of Total Liabilities |
= | Market Cap | / | Total Liabilities | |
= | 3052.382 | / | 283.189 | |
= | 10.7786 |
X5 | = | Revenue | / | Total Assets |
= | 322.711 | / | 987.368 | |
= | 0.3268 |
The zones of discrimination were as such:
Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones
Zai Lab has a Altman Z-Score of 3.25 indicating it is in Safe Zones.
Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.
Zai Lab (NAS:ZLAB) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Read more about Altman Z-Score and the original research.
Be Aware
Altman Z-Score does not apply to financial companies.
Thank you for viewing the detailed overview of Zai Lab's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Edmondson Frazor Titus Iii | officer: Chief Legal Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Joshua L Smiley | officer: Chief Operating Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Yajing Chen | officer: Chief Financial Officer | 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142 |
Rafael Amado | officer: See Remarks | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Ying Du | director, officer: Chairwoman & CEO | C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210 |
Harald Reinhart | officer: Chief Medical Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Michel Vounatsos | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Peter Wirth | director | 37 HANCOCK STREET, BOSTON MA 02114 |
John D Diekman | director | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Tao Fu | director, officer: President & COO | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Cho William Ki Chul | officer: Chief Financial Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Kai-xian Chen | director | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
From GuruFocus
By Business Wire • 08-22-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 04-15-2024
By Business Wire • 05-22-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 03-14-2024
By Business Wire • 07-16-2024
By GuruFocus Research • 05-17-2024
By Business Wire • 09-17-2024
By Business Wire • 07-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.